Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib

The Structure of Clinical Translation:Efficiency, Information, and Ethics

(2015) Jonathan Kimmelman et al.   HASTINGS CENTER REPORT

A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma

(2014) B. Rini et al.   ANNALS OF ONCOLOGY

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial

(2014) A. Adenis et al.   ANNALS OF ONCOLOGY

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours

(2014) N A G Lankheet et al.   BRITISH JOURNAL OF CANCER

A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies

(2014) Justine Yang Bruce et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma

(2014) Robert J. Motzer et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia

(2014) Vincent Castonguay et al.   GYNECOLOGIC ONCOLOGY

A Pilot Study of Hypofractionated Stereotactic Radiation Therapy and Sunitinib in Previously Irradiated Patients With Recurrent High-Grade Glioma

(2014) Evan J. Wuthrick et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

How to increase value and reduce waste when research priorities are set

(2014) Iain Chalmers et al.   LANCET

Increasing value and reducing waste in research design, conduct, and analysis

(2014) John P A Ioannidis et al.   LANCET

Clinical development success rates for investigational drugs

(2014) Michael Hay et al.   NATURE BIOTECHNOLOGY

Phase I Study of Sunitinib in Combination With Gemcitabine and Capecitabine for First-Line Treatment of Metastatic or Unresectable Renal Cell Carcinoma

(2014) J. Bellmunt et al.   ONCOLOGIST

Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a Phase II study

(2014) Carmen Balaña et al.   Targeted Oncology

Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer

(2013) Giuseppe Curigliano et al.   BREAST

Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma

(2013) Petros D. Grivas et al.   CANCER

Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients

(2013) Hye Ryun Kim et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Phase II Trial of Sunitinib in Patients With Renal Cell Cancer and Untreated Brain Metastases

(2013) Christine Chevreau et al.   Clinical Genitourinary Cancer

A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma

(2013) David S. Hong et al.   Clinical Genitourinary Cancer

A phase II study of sunitinib in advanced hepatocellular carcinoma

(2013) Carlo Barone et al.   DIGESTIVE AND LIVER DISEASE

Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial

(2013) Michele Reni et al.   EUROPEAN JOURNAL OF CANCER

Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: Results of a Phase II trial

(2013) Craig Reynolds et al.   INVESTIGATIONAL NEW DRUGS

A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07)

(2013) Markus Hutterer et al.   NEURO-ONCOLOGY

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

(2013) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Accumulating Evidence and Research Organization (AERO) model: a new tool for representing, analyzing, and planning a translational research program

(2013) Spencer Hey et al.   Trials

Development Times, Clinical Testing, Postmarket Follow-up, and Safety Risks for the New Drugs Approved by the US Food and Drug Administration

(2013) Thomas J. Moore et al.   JAMA Internal Medicine

Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma

(2012) J.- L. Lee et al.   ANNALS OF ONCOLOGY

A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy

(2012) K. H. Baumann et al.   ANNALS OF ONCOLOGY

Phase II open-label study of sunitinib in patients with advanced breast cancer

(2012) Denise A. Yardley et al.   BREAST CANCER RESEARCH AND TREATMENT

Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure

(2012) G. D. Demetri et al.   CLINICAL CANCER RESEARCH

A Phase 2 Trial of Sunitinib in Patients with Advanced Non–clear Cell Renal Cell Carcinoma

(2012) Nizar M. Tannir et al.   EUROPEAN UROLOGY

A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma

(2012) Susana M. Campos et al.   GYNECOLOGIC ONCOLOGY

Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: A single-center experience with 31 patients

(2012) Bruno Neri et al.   INTERNATIONAL JOURNAL OF UROLOGY

Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor

(2012) Tetsuhide Ito et al.   INVESTIGATIONAL NEW DRUGS

Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial

(2012) Matthias Kroiss et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

(2012) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Continuous daily sunitinib for recurrent glioblastoma

(2012) Teri Nguyen Kreisl et al.   JOURNAL OF NEURO-ONCOLOGY

A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma

(2012) Edward Pan et al.   JOURNAL OF NEURO-ONCOLOGY

A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma

(2012) Anna K. Nowak et al.   Journal of Thoracic Oncology

The Effect of Sunitinib on Primary Renal Cell Carcinoma and Facilitation of Subsequent Surgery

(2012) Brian I. Rini et al.   JOURNAL OF UROLOGY

A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer

(2012) Ji-Youn Han et al.   LUNG CANCER

A pilot study of sunitinib malate in patients with metastatic uveal melanoma

(2012) Amit Mahipal et al.   MELANOMA RESEARCH

Phase II Trial of Concurrent Sunitinib and Image-Guided Radiotherapy for Oligometastases

(2012) Charles C. L. Tong et al.   PLoS One

Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence

(2012) Juping Zhao et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Dose Escalation and Pharmacokinetics Study of Enzastaurin and Sunitinib Versus Placebo and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

(2011) Manuela Schmidinger et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC

(2011) N. G. Chau et al.   ANNALS OF ONCOLOGY

Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease

(2011) E. Jonasch et al.   ANNALS OF ONCOLOGY

Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study

(2011) K. Oechsle et al.   ANNALS OF ONCOLOGY

Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma

(2011) Anne Flörcken et al.   ANTI-CANCER DRUGS

Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma

(2011) Ana M. Molina et al.   CANCER

Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study

(2011) Steven G. DuBois et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study

(2011) S. G. DuBois et al.   CLINICAL CANCER RESEARCH

An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer

(2011) M. Moehler et al.   EUROPEAN JOURNAL OF CANCER

A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study

(2011) Jun Ho Yi et al.   EUROPEAN JOURNAL OF CANCER

Accelerating Identification and Regulatory Approval of Investigational Cancer Drugs

(2011) Laura J. Esserman et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group

(2011) Scott A. Laurie et al.   Journal of Thoracic Oncology

Phase II Trial of Sunitinib Maintenance Therapy After Platinum-Based Chemotherapy in Patients with Extensive-Stage Small Cell Lung Cancer

(2011) Bryan J. Schneider et al.   Journal of Thoracic Oncology

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

(2011) Sylvie Négrier et al.   LANCET ONCOLOGY

Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group

(2011) Rena Buckstein et al.   LEUKEMIA & LYMPHOMA

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

(2011) Eric Raymond et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase II Study of Presurgical Sunitinib in Patients With Metastatic Clear-cell Renal Carcinoma and the Primary Tumor In Situ

(2011) Axel Bex et al.   UROLOGY

A Phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC)

(2010) Viktor Grünwald et al.   ACTA ONCOLOGICA

Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma

(2010) Robert J. Motzer et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study

(2010) J. J. Biagi et al.   ANNALS OF ONCOLOGY

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer

(2010) H. Wildiers et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

(2010) Brian I. Rini et al.   CANCER

Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

(2010) L. L. Carr et al.   CLINICAL CANCER RESEARCH

Phase II Study of Sunitinib in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

(2010) Effrosyni Apostolidou et al.   Clinical Lymphoma Myeloma & Leukemia

Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma

(2010) S. Tariq Mahmood et al.   INTERNATIONAL JOURNAL OF CANCER

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate

(2010) Justine Yang Bruce et al.   INVESTIGATIONAL NEW DRUGS

Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma

(2010) Ana M. Molina et al.   INVESTIGATIONAL NEW DRUGS

Phase II study of sunitinib as second-line treatment for advanced gastric cancer

(2010) Yung-Jue Bang et al.   INVESTIGATIONAL NEW DRUGS

Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer

(2010) David J. Gallagher et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of sunitinib malate in patients with recurrent high-grade glioma

(2010) B. Neyns et al.   JOURNAL OF NEURO-ONCOLOGY

Prospective Clinical Trial of Preoperative Sunitinib in Patients With Renal Cell Carcinoma

(2010) Nicholas J. Hellenthal et al.   JOURNAL OF UROLOGY

Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06)

(2010) D. Koeberle et al.   ONCOLOGIST

A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603)

(2010) E. M. O'Reilly et al.   ONCOLOGIST

Publication Outcomes of Phase II Oncology Clinical Trials

(2009) Rasmus T. Hoeg et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Phase II study of sunitinib in men with advanced prostate cancer

(2009) M. Dror Michaelson et al.   ANNALS OF ONCOLOGY

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

(2009) S Novello et al.   BRITISH JOURNAL OF CANCER

A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer

(2009) George Fountzilas et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma

(2009) Premal H. Patel et al.   Clinical Genitourinary Cancer

7122 Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma (mRCC): preliminary results

(2009) C.H. Barrios et al.   EJC SUPPLEMENTS

Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study

(2009) Martee L. Hensley et al.   GYNECOLOGIC ONCOLOGY

A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184

(2009) Helen J. Mackay et al.   GYNECOLOGIC ONCOLOGY

Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors

(2009) Darren R. Feldman et al.   INVESTIGATIONAL NEW DRUGS

Phase II study of sunitinib malate in head and neck squamous cell carcinoma

(2009) Nicholas W. Choong et al.   INVESTIGATIONAL NEW DRUGS

Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate

(2009) Kuniaki Shirao et al.   INVESTIGATIONAL NEW DRUGS

A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and Safety

(2009) H. Uemura et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas

(2009) Suzanne George et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma

(2009) Darren R. Feldman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

(2009) Andrew X. Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01

(2009) Jean-Pascal H. Machiels et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function

(2009) Reza Khosravan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

(2009) Sandrine Faivre et al.   LANCET ONCOLOGY

Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib

(2009) Katherine A. Janeway et al.   PEDIATRIC BLOOD & CANCER

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer

(2008) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2008) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors

(2008) Matthew H. Kulke et al.   JOURNAL OF CLINICAL ONCOLOGY

Response of the Primary Tumor to Neoadjuvant Sunitinib in Patients With Advanced Renal Cell Carcinoma

(2008) Anil A. Thomas et al.   JOURNAL OF UROLOGY

Life Cycle of Translational Research for Medical Interventions

(2008) D. G. Contopoulos-Ioannidis et al.   SCIENCE